CD274 and neoplasm: Nintedanib upregulated the expression of PD-L1 and MHC-I in tumor cells, boosted the immunological recognition and immune clearance of tumor cells, and increased the infiltration and activation of immune cells in tumor tissues, thus improving the efficacy of immunotherapy and overcoming partial ICI resistance (45).